Academic Journal
أعرض في EDS

Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance

التفاصيل البيبلوغرافية
العنوان: Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance
المؤلفون: Hyun Woong Lee, Jung Il Lee, Saein Kim, Sora Kim, Hye Young Chang, Kwan Sik Lee
المصدر: BMC Gastroenterology, Vol 20, Iss 1, Pp 1-9 (2020)
بيانات النشر: BMC, 2020.
سنة النشر: 2020
المجموعة: LCC:Diseases of the digestive system. Gastroenterology
مصطلحات موضوعية: Hepatitis B virus, Hepatitis B e antigen seroclearance, Hepatitis B s antigen seroclearance, Hepatocellular carcinoma, Diseases of the digestive system. Gastroenterology, RC799-869
الوصف: Abstract Background Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance. Methods In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and laboratory results were recorded. Results The mean age at HBeAg seroclearance was 40 years (range, 20–84), and the mean follow-up duration was 5 years (range, 2–11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years from HBeAg seroclearance. Conclusions A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1471-230X
Relation: http://link.springer.com/article/10.1186/s12876-020-01236-9; https://doaj.org/toc/1471-230X
DOI: 10.1186/s12876-020-01236-9
URL الوصول: https://doaj.org/article/c92801ba2fe646f9a931fa307a8bcffe
رقم الانضمام: edsdoj.92801ba2fe646f9a931fa307a8bcffe
قاعدة البيانات: Directory of Open Access Journals
ResultId 1
Header edsdoj
Directory of Open Access Journals
edsdoj.92801ba2fe646f9a931fa307a8bcffe
943
3
Academic Journal
academicJournal
942.65625
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsdoj&AN=edsdoj.92801ba2fe646f9a931fa307a8bcffe&custid=s6537998&authtype=sso
FullText Array ( [Availability] => 0 )
Array ( [0] => Array ( [Url] => https://doaj.org/article/c92801ba2fe646f9a931fa307a8bcffe [Name] => EDS - DOAJ [Category] => fullText [Text] => View record in DOAJ [MouseOverText] => View record in DOAJ ) [1] => Array ( [Url] => https://resolver.ebscohost.com/openurl?custid=s6537998&groupid=main&authtype=ip,guest&sid=EBSCO:edsdoj&genre=article&issn=1471230X&ISBN=&volume=20&issue=1&date=20200401&spage=1&pages=1-9&title=BMC Gastroenterology&atitle=Cumulative%20incidence%20of%20hepatocellular%20carcinoma%20and%20hepatitis%20B%20surface%20antigen%20Seroclearance%20after%20Nucleos%28t%29%20ide%20analogue-induced%20hepatitis%20B%20e%20antigen%20Seroclearance&id=DOI:10.1186/s12876-020-01236-9 [Name] => Full Text Finder (s6537998api) [Category] => fullText [Text] => Full Text Finder [Icon] => https://imageserver.ebscohost.com/branding/images/FTF.gif [MouseOverText] => Full Text Finder ) )
Items Array ( [Name] => Title [Label] => Title [Group] => Ti [Data] => Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance )
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Hyun+Woong+Lee%22">Hyun Woong Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Jung+Il+Lee%22">Jung Il Lee</searchLink><br /><searchLink fieldCode="AR" term="%22Saein+Kim%22">Saein Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Sora+Kim%22">Sora Kim</searchLink><br /><searchLink fieldCode="AR" term="%22Hye+Young+Chang%22">Hye Young Chang</searchLink><br /><searchLink fieldCode="AR" term="%22Kwan+Sik+Lee%22">Kwan Sik Lee</searchLink> )
Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => BMC Gastroenterology, Vol 20, Iss 1, Pp 1-9 (2020) )
Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => BMC, 2020. )
Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 )
Array ( [Name] => Subset [Label] => Collection [Group] => HoldingsInfo [Data] => LCC:Diseases of the digestive system. Gastroenterology )
Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Hepatitis+B+virus%22">Hepatitis B virus</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatitis+B+e+antigen+seroclearance%22">Hepatitis B e antigen seroclearance</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatitis+B+s+antigen+seroclearance%22">Hepatitis B s antigen seroclearance</searchLink><br /><searchLink fieldCode="DE" term="%22Hepatocellular+carcinoma%22">Hepatocellular carcinoma</searchLink><br /><searchLink fieldCode="DE" term="%22Diseases+of+the+digestive+system%2E+Gastroenterology%22">Diseases of the digestive system. Gastroenterology</searchLink><br /><searchLink fieldCode="DE" term="%22RC799-869%22">RC799-869</searchLink> )
Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Abstract Background Hepatitis B e antigen (HBeAg) seroclearance has been considered as the treatment endpoint in HBeAg-positive patients with chronic hepatitis B (CHB). Although HBeAg seroclearance has been accomplished, some aspects are yet unclear. We investigated the cumulative incidence of hepatocellular carcinoma (HCC) and evaluated hepatitis B surface antigen (HBsAg) seroclearance in patients undergoing nucleos(t) ide analogue (NA)-induced HBeAg seroclearance. Methods In this retrospective cohort study, 203 patients with CHB were HBsAg and HBeAg seropositive before NA (entecavir or tenofovir) treatment. All patient who experienced NA -induced HBeAg seroclearance were recruited. Patients with documented HBeAg seroclearance were followed-up every 6 months. Baseline characteristics and laboratory results were recorded. Results The mean age at HBeAg seroclearance was 40 years (range, 20–84), and the mean follow-up duration was 5 years (range, 2–11). The cumulative incidence of HCC was 1.5 to 11.5% at 1 to 8 years after HBeAg seroclearance. Cirrhosis was the only significant factor for HCC development (hazard ratio [HR], 24.651; confidence interval [CI], 3.018 to 201.365; P = 0.003). The cumulative incidence of HBsAg seroclearance was 3.5 to 18.7% after 1 to 8 years from HBeAg seroclearance. Conclusions A significant proportion of patients developed HCC after NA-induced HBeAg seroclearance. The presence of liver cirrhosis at the time of HBeAg seroclearance serves as an independent factor for HCC development. Some patients with NA-induced HBeAg seroclearance achieved HBsAg seroclearance. )
Array ( [Name] => TypeDocument [Label] => Document Type [Group] => TypDoc [Data] => article )
Array ( [Name] => Format [Label] => File Description [Group] => SrcInfo [Data] => electronic resource )
Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English )
Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1471-230X )
Array ( [Name] => NoteTitleSource [Label] => Relation [Group] => SrcInfo [Data] => http://link.springer.com/article/10.1186/s12876-020-01236-9; https://doaj.org/toc/1471-230X )
Array ( [Name] => DOI [Label] => DOI [Group] => ID [Data] => 10.1186/s12876-020-01236-9 )
Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://doaj.org/article/c92801ba2fe646f9a931fa307a8bcffe" linkWindow="_blank">https://doaj.org/article/c92801ba2fe646f9a931fa307a8bcffe</link> )
Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsdoj.92801ba2fe646f9a931fa307a8bcffe )
RecordInfo Array ( [BibEntity] => Array ( [Identifiers] => Array ( [0] => Array ( [Type] => doi [Value] => 10.1186/s12876-020-01236-9 ) ) [Languages] => Array ( [0] => Array ( [Text] => English ) ) [PhysicalDescription] => Array ( [Pagination] => Array ( [PageCount] => 9 [StartPage] => 1 ) ) [Subjects] => Array ( [0] => Array ( [SubjectFull] => Hepatitis B virus [Type] => general ) [1] => Array ( [SubjectFull] => Hepatitis B e antigen seroclearance [Type] => general ) [2] => Array ( [SubjectFull] => Hepatitis B s antigen seroclearance [Type] => general ) [3] => Array ( [SubjectFull] => Hepatocellular carcinoma [Type] => general ) [4] => Array ( [SubjectFull] => Diseases of the digestive system. Gastroenterology [Type] => general ) [5] => Array ( [SubjectFull] => RC799-869 [Type] => general ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => Cumulative incidence of hepatocellular carcinoma and hepatitis B surface antigen Seroclearance after Nucleos(t) ide analogue-induced hepatitis B e antigen Seroclearance [Type] => main ) ) ) [BibRelationships] => Array ( [HasContributorRelationships] => Array ( [0] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hyun Woong Lee ) ) ) [1] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Jung Il Lee ) ) ) [2] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Saein Kim ) ) ) [3] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Sora Kim ) ) ) [4] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Hye Young Chang ) ) ) [5] => Array ( [PersonEntity] => Array ( [Name] => Array ( [NameFull] => Kwan Sik Lee ) ) ) ) [IsPartOfRelationships] => Array ( [0] => Array ( [BibEntity] => Array ( [Dates] => Array ( [0] => Array ( [D] => 01 [M] => 04 [Type] => published [Y] => 2020 ) ) [Identifiers] => Array ( [0] => Array ( [Type] => issn-print [Value] => 1471230X ) ) [Numbering] => Array ( [0] => Array ( [Type] => volume [Value] => 20 ) [1] => Array ( [Type] => issue [Value] => 1 ) ) [Titles] => Array ( [0] => Array ( [TitleFull] => BMC Gastroenterology [Type] => main ) ) ) ) ) ) )
IllustrationInfo